SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Tokyo Joe's Cafe / Anything goes
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Don Powrie who wrote (16614)5/12/1998 9:09:00 AM
From: Don Powrie  Read Replies (2) of 34592
 
>>>NEWS! Nasdaq:AKRN

Akorn Diltiazem injection approved by FDA

LINCOLNSHIRE, Ill., May 12 (Reuters) - Akorn Inc. said Tuesday the Food and Drug Administration had approved an Abbreviated New Drug Application (ANDA) for its Diltiazem HCl Injection, which treats irregular and rapid heartbeats.

Akorn said its Taylor Pharmaceuticals division has entered into a strategic alliance with Baxter Pharmaceutical Products Inc. to market Diltiazem globally.

Akorn said the Diltiazem launch, which may come this month, is the first part of an alliance in which Taylor and Baxter will jointly develop, manufacture and market four injectable
products with current sales in excess of $200 million.

The four are:

-- Diltiazem, which is indicated for atrial flutter and for paroxysmal supraventricular tachycardia;

-- Labetalol HCl Injection, for control of blood pressure in severe hypertension;

-- Ketorolac Tromethamine Injection, for pain management;

-- Amrinone Lactate Injection, for the management of congestive heart failure.

Other injectable products under the alliance with Baxter will be launched once ANDA approvals are obtained.

Akorn manufactures and markets sterile ophthalmic and injectable pharmaceuticals, and markets and distributes ophthalmic products.

More Quotes and News: Akorn Inc (Nasdaq:AKRN - news)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News